Main Menu

Professor Johann de Bono given 2018 AACR award for outstanding achievement

Professor Johann de Bono

Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London and an honorary consultant at The Royal Marsden NHS Foundation Trust, has been chosen to receive the 2018 AACR–Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research.

The award is a significant mark of esteem for Professor de Bono, and recognises his outstanding and world-leading research in the clinical development of personalised cancer treatments.

The AACR–Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research was established in 1996, and is named for the late Dr Joseph Burchenal, a past president of the AACR, and a major figure in clinical cancer research and chemotherapy.

As the 2018 recipient of the award, Professor de Bono today gives a lecture at the AACR conference, which is titled 'Re-envisioning clinical cancer research'.

We are training the next generation of researchers; by supporting a PhD studentship, you could help us advance personalised prostate cancer treatment.

Read more

Re-envisioning clinical cancer research

Professor de Bono, who leads the Prostate Cancer Targeted Therapy Group and the Cancer Biomarkers laboratory team, has spent many years re-envisioning clinical cancer research.

He specialises in developing new molecularly targeted therapies and focuses especially on improving treatment for prostate cancer patients, and has been involved in developing more than 100 potential new drugs over the past decade, several of which are now available to patients.

He led pivotal clinical trials for the prostate cancer drugs abiraterone, cabazitaxel and enzalutamide, which have benefited hundreds of thousands of men with advanced prostate cancer.

Deeply honoured to receive prestigious award

Professor de Bono said: “I am deeply honoured to be chosen to receive such a prestigious award.

“My goal has always been to make a real impact on the lives of cancer patients, and I’m delighted to have my efforts recognised by the AACR.

“I’d like to thank my colleagues at the ICR and The Royal Marsden, without whom this would not have been possible. 

“It’s a testament to the strong partnership between the two organisations, and the opportunities for multidisciplinary research that this provides.”


abiraterone Johann de Bono AACR cabazitaxel
comments powered by Disqus